文献速递泌尿男性生殖肿瘤

中危前列腺癌:雄激素剥夺治疗联合放疗的随机III期试验

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.
PubMed 文献 · Eur J Cancer · 2020-12-03

该随机III期试验纳入600例中危前列腺癌患者,比较6个月ADT联合70Gy放疗、ADT联合76Gy剂量递增放疗与单用76Gy放疗。中位随访11.3年显示,单用76Gy放疗的生化失败率、前列腺癌进展率和前列腺癌死亡率均更高,但三组总生存无显著差异;76Gy组晚期胃肠道毒性≥II级更高。

要点

  • 中危前列腺癌加6个月ADT可显著降低生化失败和前列腺癌死亡风险。
  • ADT联合70Gy与ADT联合76Gy在疾病控制上无显著差异。
  • 76Gy放疗相比70Gy增加晚期胃肠道毒性≥II级,泌尿毒性无差异。

核心结论

  • 在中危前列腺癌中,与单用76Gy剂量递增放疗相比,加用6个月ADT联合70Gy或76Gy放疗显著改善生化失败并似降低前列腺癌死亡风险,但总生存无差异。
  • ADT联合70Gy方案在疾病控制有效的同时具有更好的胃肠道毒性特征。

研究设计与样本

  • 随机III期三臂试验,2000年12月至2010年9月纳入600例中危前列腺癌患者。
  • 三组分别为6个月ADT联合70Gy放疗、ADT联合76Gy剂量递增放疗、单用76Gy剂量递增放疗。
  • 主要终点为生化失败,次要终点为总生存和毒性,放疗毒性采用RTOG/EORTC标准评估。

主要发现

  • 中位随访11.3年(四分位距10.9-11.7),单用76Gy组、ADT+70Gy组和ADT+76Gy组的生化失败率分别为32%、18%和14%(p<0.001)。
  • 三组前列腺癌进展率分别为12%、4.5%和3.3%(p=0.001),前列腺癌死亡率分别为6.5%、3.0%和1.5%(p=0.03)。
  • ADT+70Gy与ADT+76Gy两组在上述结局间无显著差异,三组总生存无显著差异。
  • 76Gy放疗相比70Gy增加晚期胃肠道毒性≥II级(16% vs 5.3%,p<0.001),晚期泌尿生殖毒性无统计学差异。

关键数值与推荐

  • 中危前列腺癌患者接受6个月ADT联合70Gy或76Gy放疗,相比单用76Gy放疗,可显著降低生化失败率(14%-18% vs 32%,p<0.001)。
  • ADT联合70Gy方案与ADT联合76Gy方案在生化失败、前列腺癌进展和前列腺癌死亡方面无显著差异。
  • 76Gy放疗相比70Gy放疗,晚期胃肠道毒性≥II级发生率更高(16% vs 5.3%,p<0.001)。

临床怎么用

  • 中危前列腺癌接受放疗时,应考虑联合6个月ADT以改善生化控制和降低前列腺癌死亡风险。
  • 选择ADT联合70Gy放疗可在保持有效疾病控制的同时减少晚期胃肠道毒性。
  • 剂量递增至76Gy需权衡更高的晚期胃肠道毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of androgen deprivation therapy (ADT) in combination with radiotherapy (RT) in intermediate-risk prostate cancer (IRPC) remains controversial, particularly in patients receiving dose-escalated RT (DERT). We compared outcomes between patients with IRPC treated with ADT and two different doses of RT vs. RT alone. METHODS: From December 2000 to September 2010, 600 patients with IRPC were randomised to a three-arm trial consisting of 6 months of ADT plus RT 70 Gy (ADT + RT70) vs. ADT plus a DERT of 76 Gy (ADT + DERT76) vs. DERT of 76 Gy alone (DERT76). Primary end-point was biochemical failure (BF), and secondary end-points were overall survival (OS) and toxicity. RT toxicity was assessed by Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer criteria. FINDINGS: With a median follow-up of 11.3 years (interquartile range: 10.9-11.7), patients receiving DERT76 alone, compared with patients receiving ADT + RT70 and ADT + DERT76, had higher rates of BF (32%, 18% and 14%, respectively, p < 0.001), higher rates of prostate cancer progression (12%, 4.5% and 3.3%, respectively, p = 0.001) and more deaths due to prostate cancer (6.5%, 3.0% and 1.5%, respectively, p = 0.03) with no significant difference seen between ADT + RT70 and ADT + DERT76. There was no significant difference in OS between the 3 arms. A higher dose of RT (76 Gy) increased late gastrointestinal (GI) toxicity grade ≥ II compared with lower dose (70 Gy) (16% vs 5.3%, p < 0.001) with no statistical difference for late genitourinary toxicity. INTERPRETATION: In IRPC, the addition of 6 months of ADT to RT70 or DERT76 significantly improves BF and appears to decrease the risk of death from prostate cancer compared with DERT76 alone with no difference in OS. In the setting of IRPC, ADT plus RT 70 Gy yields effective disease control with a better GI toxicity profile. Clinicaltrials.gov#NCT00223145.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nabid A, Carrier N, Vigneault E, et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. Eur J Cancer. 2020. PMID: 33279855. doi:10.1016/j.ejca.2020.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。